Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.

MLA

Hill, Louise F., et al. “Optimised versus Standard Dosing of Vancomycin in Infants with Gram-Positive Sepsis (NeoVanc): A Multicentre, Randomised, Open-Label, Phase 2b, Non-Inferiority Trial.” The Lancet. Child & Adolescent Health, vol. 6, no. 1, Jan. 2022, pp. 49–59. EBSCOhost, https://doi.org/10.1016/S2352-4642(21)00305-9.

APA

Hill, L. F., Clements, M. N., Turner, M. A., Donà, D., Lutsar, I., Jacqz-Aigrain, E., Heath, P. T., Roilides, E., Rawcliffe, L., Alonso-Diaz, C., Baraldi, E., Dotta, A., Ilmoja, M.-L., Mahaveer, A., Metsvaht, T., Mitsiakos, G., Papaevangelou, V., Sarafidis, K., Walker, A. S., & Sharland, M. (2022). Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. The Lancet. Child & Adolescent Health, 6(1), 49–59. https://doi.org/10.1016/S2352-4642(21)00305-9

Chicago

Hill, Louise F, Michelle N Clements, Mark A Turner, Daniele Donà, Irja Lutsar, Evelyne Jacqz-Aigrain, Paul T Heath, et al. 2022. “Optimised versus Standard Dosing of Vancomycin in Infants with Gram-Positive Sepsis (NeoVanc): A Multicentre, Randomised, Open-Label, Phase 2b, Non-Inferiority Trial.” The Lancet. Child & Adolescent Health 6 (1): 49–59. doi:10.1016/S2352-4642(21)00305-9.